Development of organ- and non-organ-specific autoantibodies has been reported in Hepatitis C virus patients treated with interferon-α plus/minus ribavirin.
Dr Dalekos and colleagues from Greece assessed the prevalence of Hepatitis C virus-treated patients.
The team investigated whether the titre of gastric parietal autoantibodies and non-organ-specific autoantibody were affected by therapy in these patients.
The team also evaluated if the development of these antibodies carries any clinical significance on the response to treatment.
The investigators noted that few studies in adults have been strictly designed to address the above hypothesis.
|Increased smooth-muscle antibody titres were associated with worst treatment response|
|Alimentary Pharmacology & Therapeutics|
Samples were taken at 3 time-points, including baseline, end of treatment, end of follow-up.
The investigators took samples from 102 Hepatitis C virus patients.
Of these, 39 were sustained responders, 26 were relapsers, 33 were non-responders, and 4 were lost in follow-up.
The investigators evaluated these patients for gastric parietal autoantibodies.
The team assessed non-organ-specific autoantibody by indirect immunofluorescence, commercial, and in-house enzyme-linked immunosorbent assays.
The investigators found that sustained virological and biochemical response was associated with antinuclear antibody absence.
The team observed that sustained virological response was also associated with a decrease of smooth-muscle antibody titres during therapy.
Sustained virological response was associated with gastric parietal autoantibodies negativity at baseline.
However, after multivariate analysis only antinuclear antibody positivity at the end of treatment was associated with worst treatment response.
The investigators noted that increased smooth-muscle antibody titres were associated with worst treatment response.
The team observed that both of these factors were independent of known factors of worst treatment outcome.
Dr Dalekos' team concludes, “We were able to demonstrate a negative correlation between the efficacy of anti-viral treatment for Hepatitis C virus, and the presence of antinuclear antibody and smooth-muscle antibody before treatment, or their increase during therapy.”